Posttranscriptional regulation of expression of plasminogen activator inhibitor type-1 by sphingosine 1-phosphate in HepG2 liver cells

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1819, Issue 11-12, 2012, Pages 1132-1141

  Iwaki, Soichiro ^a   Yamamura, Shuhei ^a   Asai, Moyoko ^a   Sobel, Burton E ^b   Fujii, Satoshi ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Plasminogen activator inhibitor 1; Posttranscriptional regulation; RNA binding protein; S1P

Indexed keywords

LUCIFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPHINGOSINE 1 PHOSPHATE;

3' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

3' UNTRANSLATED REGIONS; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; LYSOPHOSPHOLIPIDS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA STABILITY; RNA-BINDING PROTEINS; SPHINGOSINE;

EID: 84867429227     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2012.07.001     Document Type: Article

References (39)

1. Alessim M., Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb. Haemost. 2008, 99:995-1000.
2. Hamsten A., Wiman B., de Faire U., Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med. 1985, 313:1557-1563.
3. Schneider D., Hayes M., Wadsworth M., Taatjes H., Rincon M., Taatjes D., Sobel B. Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1). J. Histochem. Cytochem. 2004, 52:1091-1099.
4. Vulin A., Stanley F. Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. J. Biol. Chem. 2004, 279:25172-25178.
5. Asakura T., Iwaki S., Okada H., Sobel B., Fujii S. Posttranscriptional regulation of expression of plasminogen activator inhibitor type-1 by cAMP in HepG2 liver cells. J. Biochem. 2011, 150:687-694.
6. Bryan L., Paugh B., Kapitonov D. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness. Mol. Cancer Res. 2008, 6:1469-1477.
7. Lee M., Hammad S., Semler A., Luttrell L., Lopes-Virella M., Klein R. HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate. J. Lipid Res. 2010, 51:2619-2628.
8. Misquitta C., Iyer V., Werstiuk E., Grover A. The role of 3'-untranslated region (3'-UTR) mediated mRNA stability in cardiovascular pathophysiology. Mol. Cell. Biochem. 2001, 224:53-67.
9. Chen C., Shyu A. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem. Sci. 1995, 20:465-470.
10. Lagnado C., Brown C., Goodall G. AUUUA is not sufficient to promote poly(A) shortening and degradation of an mRNA: the functional sequence within AU-rich elements may be UUAUUUA(U/A)(U/A). Mol. Cell. Biol. 1994, 14:7984-7995.
11. Lewis T., Gueydan C., Huez G., Toulme J., Kruys V. Mapping of a minimal AU-rich sequence required for lipopolysaccharide-induced binding of a 55-kDa protein on tumor necrosis factor-α mRNA. J. Biol. Chem. 1998, 273:13781-13786.
12. Zubiaga A., Belasco J., Greenberg M. The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Mol. Cell. Biol. 1995, 15:2219-2230.
13. Lai W., Carrick D., Blackshear P. Influence of nonameric AU-rich tristetraprolin-binding sites on mRNA deadenylation and turnover. J. Biol. Chem. 2005, 280:34365-34377.
14. Heaton J., Dlakic W., Dlakic M., Gelehrter T. Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the type-1 plasminogen activator inhibitor mRNA. J. Biol. Chem. 2001, 276:3341-3347.
15. 2 expression during embryonal development and primitive endoderm differentiation of F9 cells. Biochem. Biophys. Res. Commun. 2006, 344:852-858.
16. Fattal P., Billadello J. Species-specific differential cleavage and polyadenylation of plasminogen activator inhibitor type 1 hnRNA. Nucleic Acids Res. 1993, 21:1463-1466.
17. Bosma P., Kooistra T. Different induction of two plasminogen activator inhibitor 1 mRNA species by phorbol ester in human hepatoma cells. J. Biol. Chem. 1991, 266:17845-17849.
18. Hopkins W., Billadello J. Multiple transforming growth factor-β-inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in HepG2 cells. J. Biol. Chem. 1991, 266:1092-1100.
19. Fattal P., Schneider D., Sobel B., Billadello J. Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J. Biol. Chem. 1992, 267:12412-12415.
20. Bakheet T., Frevel M., Williams B.R., Greer W., Khabar K.S. ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acids Res. 2001, 29:246-254.
21. Ginsburg D., Zeheb R., Yang A. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J. Clin. Invest. 1986, 78:1673-1680.
22. Ny T., Sawdey M., Lawrence D. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:6776-6780.
23. Doller A., Gauer S., Sobkowiak E., Geiger H., Pfeilschifter J., Eberhardt W. Angiotensin II induces renal plasminogen activator inhibitor-1 and cyclooxygenase-2 expression post-transcriptionally via activation of the mRNA-stabilizing factor human-antigen R. Am. J. Pathol. 2009, 174:1252-1263.
24. Shetty S., Shetty P., Idell S., Velusamy T., Bhandary Y., Shetty R. Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. J. Biol. Chem. 2008, 283:19570-19580.
25. Bedabrata S., Qiaoran X., Cheng H., Robert J. Selective degradation of AU-rich mRNAs promoted by the p37 AUF1 protein isoform. Mol. Cell. Biol. 2003, 23:6685-6693.
26. Yin K., Deng X., Mo Z., Zhao G., Jiang J., Cui L., Tan C., Wen G., Fu Y., Tang C. Tristetraprolin-dependent post-transcriptional regulation of inflammatory cytokine mRNA expression by apolipoprotein A-I: role of ATP-binding membrane cassette transporter A1 and signal transducer and activator of transcription 3. J. Biol. Chem. 2011, 286:13834-13845.
27. Yu H., Stasinopoulos S., Leedman P., Medcalf R. Inherent instability of plasminogen activator inhibitor type 2 mRNA is regulated by tristetraprolin. J. Biol. Chem. 2003, 278:13912-13918.
28. Sawaoka H., Dixon D., Oates J., Boutaud O. Tristetraprolin binds to the 3'-untranslated region of cyclooxygenase-2 mRNA a polyadenylation variant in a cancer cell line lacks the binding site. J. Biol. Chem. 2003, 278:13928-13935.
29. Subramaniam K., Ooi L., Hui K. Transcriptional down-regulation of IGFBP-3 in human hepatocellular carcinoma cells is mediated by the binding of TIA-1 to its AT-rich element in the 30-untranslated region. Cancer Lett. 2010, 297:259-268.
30. Dixon D., Balch G., Kedersha N., Anderson P., Zimmerman G., Beauchamp R., Prescott S. Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1. J. Exp. Med. 2003, 198:475-481.
31. Kojima S., Matsumoto K., Hirose M., Shimada M., Nagano M., Shigeyoshi Y., Hoshino S., Ui-Tei K., Saigo K., Green C., Sakaki Y., Tei H. LARK activates posttranscriptional expression of an essential mammalian clock protein, PERIOD1. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1859-1864.
32. Johann A., Weigert A., Eberhardt W., Kuhn A., Barra V., Knethen A., Pfeilschifter J., Brune B. Apoptotic cell-derived sphingosine-1-phosphate promotes HuR-dependent cyclooxygenase-2 mRNA stabilization and protein expression. J. Immunol. 2008, 180:1239-1248.
33. Heberlein K., Han J., Straub A., Best A., Kaun C., Wojta J., Isakson B. A novel mRNA binding protein complex promotes localized plasminogen activator inhibitor-1 accumulation at the myoendothelial junction. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1271-1279.
34. Tillmann-Bogush M., Heaton J., Gelehrter T. Cyclic nucleotide regulation of PAI-1 mRNA stability. Identification of cytosolic proteins that interact with an a-rich sequence. J. Biol. Chem. 1999, 274:1172-1179.
35. Sobue S., Murakami M., Banno Y., Ito H., Kimura A., Gao S., Furuhata A., Takagi A., Kojima T., Suzuki M., Nozawa Y., Murate T. v-Src oncogene product increases sphingosine kinase 1 expression through mRNA stabilization: alteration of AU-rich element-binding proteins. Oncogene 2008, 27:6023-6033.
36. Watanabe S., Takeshige K., Muta T. A cis-element in the 3'-untranslated region of IkappaB-zeta mRNA governs its stimulus-specific expression. Biochem. Biophys. Res. Commun. 2007, 356:785-791.
37. Dimova E., Jakubowska M., Kietzmann T. CREB binding to the hypoxia-inducible factor-1 responsive elements in the plasminogen activator inhibitor-promoter mediates the glucagon effect. Thromb. Haemost. 2007, 98:296-303.
38. Sobel B., Taatjes D., Schneider D. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1979-1989.
39. Schnitzer S., Weigert A., Zhou J., Brüne B. Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. Mol. Cancer Res. 2009, 7:393-401.